Michael Andrew Morse MD

Cardiology•Nashville, TN

Adult Congenital Heart Disease, Interventional Cardiology

Physician

Join to View Full Profile

4230 Harding PikeSte 535Nashville, TN 37205
Phone+1 615-222-3945
Fax+1 615-565-6748

Education & Training

McGaw Medical Center of Northwestern UniversityFellowship, Interventional Cardiology, 2012 - 2013
Emory University School of MedicineFellowship, Interventional Cardiology, 2011 - 2012
University of North Carolina HospitalsFellowship, Cardiovascular Disease, 2008 - 2011
McGaw Medical Center of Northwestern UniversityResidency, Internal Medicine, 2005 - 2008
Virginia Commonwealth University School of MedicineClass of 2005

Certifications & Licensure

TN State Medical License 2013 - 2027
IL State Medical License 2005 - 2014
NC State Medical License 2008 - 2013
American Board of Internal Medicine Cardiovascular Disease
American Board of Internal Medicine Interventional Cardiology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014

Clinical Trials

Flt3L in Treating Patients With Metastatic Colorectal Cancer Start of enrollment: 1998 Jun 01
Completed
Phase 1
Biological Therapy in Stage I, Stage II, or Stage III Surgically Resected Pancreatic Cancer Start of enrollment: 1998 Jun 01
Terminated
Phase 1
Biological Therapy in Treating Patients With Advanced Cancer Start of enrollment: 2000 Feb 01
Completed
Not Applicable
Vaccine Therapy in Treating Patients With Liver or Lung Metastases From Colorectal Cancer Start of enrollment: 2005 Feb 01
Completed
Phase 2
Denileukin Diftitox Followed by Vaccine Therapy in Treating Patients With Metastatic Cancer Start of enrollment: 2005 Sep 01
Completed
Phase 1
A Phase I Study of Ovarian Cancer Peptides Plus GM-CSF and Adjuvant With Ovarian, Tubal or Peritoneal Cancer Start of enrollment: 2007 Mar 01
Completed
Phase 1
Oxaliplatin, Capecitabine, and Cetuximab in Treating Patients With Advanced Liver Cancer Start of enrollment: 2006 Oct 01
Completed
Phase 2
CMV pp65 Specific T Cell Adoptive Immunotherapy in Allogeneic Stem Cell Transplantation for Malignant Disease Start of enrollment: 2005 Aug 01
Terminated
Phase 1
A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Transplantation Start of enrollment: 2007 Jun 01
Terminated
Phase 1
Study to Assess dHER2+AS15 Cancer Vaccine Given in Combination With Lapatinib to Patients With Metastatic Breast Cancer Start of enrollment: 2009 Jul 01
Completed
Phase 1, Phase 2
Study of Pegylated Liposomal Doxorubicin and Temsirolimus in Patients With Advanced Hepatocellular Cancer Start of enrollment: 2011 Jun 01
Withdrawn
Phase 2
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy Start of enrollment: 2011 Aug 01
Completed
A Phase I Study To Evaluate The Antitumor Activity And Safety Of AVX901 Start of enrollment: 2012 Feb 01
Completed
Phase 1
HD IL-2 + Ipilimumab in Patients With Metastatic Melanoma Start of enrollment: 2013 May 01
Terminated
Phase 4
A Study of Niclosamide in Patients With Resectable Colon Cancer Start of enrollment: 2017 Nov 07
Terminated
Phase 1
ACURATE IDE: Safety and Effectiveness Study of ACURATE Valve for Transcatheter Aortic Valve Replacement Start of enrollment: 2019 Jun 10
ACTIVE_NOT_RECRUITING
NA
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

16 citations
One-Year Outcomes From the CLASP IID Randomized Trial for Degenerative Mitral Regurgitation.
Firas Zahr, Robert L Smith, Linda D Gillam, Scott Chadderdon, Raj Makkar
JACC. Cardiovascular Interventions. 2023-10-26
21 citations
Transcatheter Edge-to-Edge Repair in 5,000 Patients With Secondary Mitral Regurgitation: COAPT Post-Approval Study.
Kashish Goel, JoAnn Lindenfeld, Raj Makkar, Hursh Naik, Satya Atmakuri
Journal of the American College of Cardiology. 2023-09-26
27 citations
Expanding the Spectrum of TEER Suitability: Evidence From the EXPAND G4 Post Approval Study.
Jason H Rogers, Federico Asch, Paul Sorajja, Paul Mahoney, Matthew J Price
JACC. Cardiovascular Interventions. 2023-06-26

Grant Support

Active Immunotherapy With Pox Vector Modified DCNational Cancer Institute2004–2008
Vaccination With Regulatory T Cell DepletionNational Cancer Institute2006–2007
Dexasome Based Immunotherapy Of Lung CancerNational Cancer Institute2001–2002

Michael Andrew Morse MD

Dr. Morse is on Doximity

Education & Training

Certifications & Licensure

Awards, Honors, & Recognition

Clinical Trials

Publications & Presentations

Grant Support

Viewing the full profile is available to verified healthcare professionals only.